KR102197858B1 - Composition for preventing or treating psoriasis comprising herb mixtures - Google Patents
Composition for preventing or treating psoriasis comprising herb mixtures Download PDFInfo
- Publication number
- KR102197858B1 KR102197858B1 KR1020190102010A KR20190102010A KR102197858B1 KR 102197858 B1 KR102197858 B1 KR 102197858B1 KR 1020190102010 A KR1020190102010 A KR 1020190102010A KR 20190102010 A KR20190102010 A KR 20190102010A KR 102197858 B1 KR102197858 B1 KR 102197858B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- extract
- present
- pharmaceutical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims description 26
- 210000002510 keratinocyte Anatomy 0.000 claims description 22
- 239000009122 Saeng-Ji-Hwang Substances 0.000 claims description 17
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 16
- 229940010454 licorice Drugs 0.000 claims description 16
- 210000003491 skin Anatomy 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052737 gold Inorganic materials 0.000 claims description 11
- 239000010931 gold Substances 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 11
- 229910052709 silver Inorganic materials 0.000 claims description 11
- 239000004332 silver Substances 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 4
- 241000125175 Angelica Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 16
- 241000124501 Paeonia obovata var. japonica Species 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 4
- 235000008078 Arctium minus Nutrition 0.000 abstract description 3
- 244000294263 Arctium minus Species 0.000 abstract description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 abstract description 2
- 241000657480 Crataegus pinnatifida Species 0.000 abstract description 2
- 244000167230 Lonicera japonica Species 0.000 abstract description 2
- 235000017617 Lonicera japonica Nutrition 0.000 abstract description 2
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 2
- 241000906577 Actaea heracleifolia Species 0.000 abstract 1
- 240000001810 Angelica gigas Species 0.000 abstract 1
- 235000018865 Angelica gigas Nutrition 0.000 abstract 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 1
- 241000229182 Ledebouriella seseloides Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 241000951376 Schizonepeta tenuifolia Species 0.000 abstract 1
- 241001551940 Scrophularia buergeriana Species 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 239000012676 herbal extract Substances 0.000 description 28
- 102100030703 Interleukin-22 Human genes 0.000 description 25
- 108010074109 interleukin-22 Proteins 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 9
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- -1 pH adjusters Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 102100028314 Filaggrin Human genes 0.000 description 7
- 101710088660 Filaggrin Proteins 0.000 description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 description 7
- 102000007236 involucrin Human genes 0.000 description 7
- 108010033564 involucrin Proteins 0.000 description 7
- 229940124595 oriental medicine Drugs 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 240000002045 Guettarda speciosa Species 0.000 description 6
- 108050003558 Interleukin-17 Proteins 0.000 description 6
- 102000013691 Interleukin-17 Human genes 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 description 4
- 102000004140 Oncostatin M Human genes 0.000 description 4
- 108090000630 Oncostatin M Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000208173 Apiaceae Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101000614442 Homo sapiens Keratin, type I cytoskeletal 16 Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000003130 Arctium lappa Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 241001092040 Crataegus Species 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000087799 Koma Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 241001106477 Paeoniaceae Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000020717 hawthorn extract Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000009472 lonicerae flos Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- ROMPPAWVATWIKR-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2C=CC(Cl)=CC=2)=N1 ROMPPAWVATWIKR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000234646 Cyperaceae Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010066364 Keratin-16 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940104299 cimicifugae rhizoma Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Abstract
Description
본 발명은 혼합 생약 추출물을 유효성분으로 포함하는 건선 예방, 개선 또는 치료용 조성물로서, 보다 상세하게는 갈근, 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개 및 화피의 혼합 추출물을 포함하는 건선 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention is a composition for preventing, improving or treating psoriasis comprising a mixed herbal extract as an active ingredient, and more specifically, Galgeun, Licorice, Geumeunhwa, Angelica, Bangpung, Baekjak, Baekjiryo, Sansa, Saengjihwang, Horseback riding, Friendship It relates to a composition for preventing, improving or treating psoriasis comprising a mixed extract of Hyeonsam, Hyeonggae and Hwapi.
건선(Psoriasis)은 각질 세포의 이상 증식, 다양한 염증성 세포, 특히 침윤(infiltration)된 T 세포가 이상적인 면역반응을 나타내어 각질 형성 세포(keratinocyte)의 비정상적인 증식 및 변화된 분화에 의해서 나타나는 만성 염증성 피부질환으로서 건선의 정확한 병인은 알려져 있지 않다. Psoriasis is a chronic inflammatory skin disease caused by abnormal proliferation and changed differentiation of keratinocytes due to abnormal proliferation of keratinocytes, various inflammatory cells, especially infiltrated T cells, showing an ideal immune response. The exact etiology of is unknown.
항원 자극이 선천성 면역세포의 활성화를 유도하고, 그 결과로 피부에서 전염증성 사이토카인(proinflammatory cytokine)이 생성되면 도움 T1 및 T17 세포의 분화를 일으켜 도움 T1 및 T17 세포가 활성화되고 여러가지 사이토카인(IL-1, TNF, IL-8, IL-6 등)을 분비한다. 이는 피부의 각질 형성 세포를 자극하게 되고 이를 통해 각질 형성 세포가 빠르게 증식하고 염증을 일으키게 되므로 비듬과 같은 비정상적인 각질이 겹겹이 쌓여 건선이 발생한다. 각질 형성 세포에서 분비되는 IL-17 및 IL-22는 전염증성 사이토카인 및 케모카인(chemokine)의 생성을 증가시켜 건선의 염증을 촉진한다. IL-17 및 IL-22의 분비를 통해 각질 세포를 활성화하고, 활성화된 각질 세포는 많은 염증성 사이토카인/케모카인 전구체를 생산하여 건선 촉발을 유도한다.When antigen stimulation induces the activation of innate immune cells, and as a result, proinflammatory cytokine is produced in the skin, it causes the differentiation of the helper T1 and T17 cells to activate the helper T1 and T17 cells, and various cytokines (IL -1, TNF, IL-8, IL-6, etc.) are secreted. This stimulates the keratinocytes of the skin, and through this, the keratinocytes rapidly proliferate and cause inflammation, so abnormal keratin such as dandruff is piled up and psoriasis occurs. IL-17 and IL-22 secreted by keratinocytes promote inflammation of psoriasis by increasing the production of proinflammatory cytokines and chemokines. It activates keratinocytes through the secretion of IL-17 and IL-22, and the activated keratinocytes induce psoriasis triggering by producing many inflammatory cytokine/chemokine precursors.
건선의 일반적인 치료에는 약을 직접 피부에 바르는 국소치료, 광선을 이용한 광치료, 면역억제제나 스테로이드 제제의 약을 복용하는 전신치료 등이 있다. 국소 치료는 스테로이드, 콜타르, 안트랄린, 비타민 D3 및 그의 유사체, 레티노이드 등을 사용하며, 이러한 국소 스테로이제제는 피부가 엷은 노인이나 소아에서 피부의 위축을 유발하고, 얼굴, 가슴, 등에 스테로이드 여드름을 유발하며, 뇌하수체-부신측을 억제하여 성장 지연과 의인성 Cushing 증후군, 골다공증, 무혈성 괴사, 약물 상호작용면역반응 감소, 성장장애 등의 부작용이 발생할 수 있다. 또한 스테로이드는 내성을 유도할 수 있어 이후의 스테로이드 치료에 영향을 준다. 광선 요법은 자외선 B 또는 자외선 A와 함께 쏘랄렌의 투여를 포함하며, 피부가 빨리 노화되고, 피부암 발병률이 증가된다는 단점이 있다. 중증 건선에는 사이클로스포린과 같은 면역조절제를 투여하지만 이 또한 장시간 사용에 따른 신장독성(nephrotoxicity)이나 고혈압을 일으킬 수 있기 때문에 주의 깊은 관찰이 필요하다. 이와 같이, 기존에 사용되던 건선의 치료 방법들은 대부분 증세를 완화시키는 효과는 있으나 근본적인 치료법은 되지 못하고 여러 부작용을 가지고 있다.Common treatments for psoriasis include topical treatment in which drugs are applied directly to the skin, phototherapy using light, and systemic treatment with immunosuppressants or steroid drugs. For topical treatment, steroids, coal tar, anthraline, vitamin D3 and its analogs, retinoids, etc. are used.These topical steroids cause skin atrophy in the elderly or children with thin skin, and steroids on the face, chest, etc. It causes acne and suppresses the pituitary-adrenal side, which can cause side effects such as delayed growth, iatrogenic Cushing syndrome, osteoporosis, avascular necrosis, decreased immune response to drug interactions, and growth disorders. In addition, steroids can induce tolerance, which affects subsequent steroid treatment. Phototherapy involves the administration of psoralen with ultraviolet B or ultraviolet A, and has the disadvantage that the skin ages quickly and the incidence of skin cancer is increased. Immunomodulators such as cyclosporine are administered to severe psoriasis, but careful observation is required because this can also cause nephrotoxicity or high blood pressure following prolonged use. As described above, most of the existing treatment methods for psoriasis have the effect of alleviating symptoms, but they are not fundamental treatments and have several side effects.
따라서, 건선의 예방 또는 치료에 효과적으로 사용할 수 있는 구체적인 치료방법이 존재하지 않으므로 본 출원의 발명자들은 혼합 생약 추출물을 포함하는 조성물이 부작용이 없으면서도 효과적으로 건선을 예방, 개선 또는 치료하는 효과가 있음을 확인하여 본 발명을 완성하였다. Therefore, since there is no specific treatment method that can be effectively used for the prevention or treatment of psoriasis, the inventors of the present application confirmed that the composition containing the mixed herbal extract is effective in preventing, improving, or treating psoriasis effectively without side effects. Thus, the present invention was completed.
본 발명의 일 목적은 혼합 생약 추출물을 포함하는 건선의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of psoriasis comprising a mixed herbal extract.
본 발명의 다른 목적은 혼합 생약 추출물을 포함하는 건선의 예방 또는 개선용 건강기능식품을 제공하는 것이다.Another object of the present invention is to provide a health functional food for preventing or improving psoriasis comprising a mixed herbal extract.
본 발명의 또 다른 목적은 혼합 생약 추출물을 포함하는 건선의 예방 또는 개선용 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition for preventing or improving psoriasis comprising a mixed herbal extract.
본 발명의 일 양상은 갈근, 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개 및 화피의 혼합 추출물을 유효성분으로 포함하는 건선 예방 또는 치료용 약학적 조성물을 제공한다.One aspect of the present invention is for the prevention or treatment of psoriasis comprising a mixed extract of Galgeun, Licorice, Geumeunhwa, Angelica, Bangpung, Baekjiryo, Sansa, Saengjihwang, Horseback Riding, Woobangja, Cheongung, Hyeonsam, Hyeonggae and Hwapi as an active ingredient Provides a pharmaceutical composition.
본 발명의 일 구체예에서, 갈근, 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개, 또는 화피는 상업적으로 판매되는 것을 구입하여 사용하거나, 자연에서 채취 또는 재배된 것을 사용할 수 있다.In one embodiment of the present invention, galgeun, licorice, gold and silver coins, angelica, windbreak, count peony, baekjiryyeo, sansa, saengjihwang, horseback riding, woobangja, cheongoong, hyeonsam, hyeonggae, or hwapi are commercially sold and used, What is harvested or cultivated in nature can be used.
갈근(葛根, Puerariae Radix)은 콩과(Leguminosae)에 속하는 다년생 덩굴나무인 칡(Pueraria lobata)의 뿌리로서 열을 내리고 근육을 풀어주며 피부를 열어 땀을 나게 하며 주독을 풀어주고 갈증과 식체를 내리는 효능이 있으며, 한방에서는 비염, 편도염, 숙취제거, 당뇨병, 고혈압, 관상동맥경화증, 협심증, 혈압강하, 콜레스테롤 저해 등에 이용되고 있고 이러한 효과를 관찰한 여러 연구들이 보고된 바 있다. Puerariae Radix is the root of Pueraria lobata, a perennial vine belonging to the leguminosae, which lowers heat, releases muscles, opens the skin to sweat, relieves alcoholism, and reduces thirst and food. In oriental medicine, it is used for rhinitis, tonsillitis, hangover removal, diabetes, high blood pressure, coronary atherosclerosis, angina, lowering blood pressure, and inhibiting cholesterol, and several studies have been reported to observe this effect.
감초(甘草, Glycyrrhizae Radix et Rhizoma)는 콩과에 속하는 여러해살이풀로서 일반적으로, 중국 북부, 시베리아, 이태리 남부, 만주, 몽고 등지에 자생 또는 재배된다. 감초는 모든 한약처방에서 독성을 줄이는 성분으로 들어가고 진해제로 쓰이는 약초 중 하나이고, 유럽에서는 담배나 껌 그리고 사탕 등에 단맛을 내기 위해 사용하기도 한다.Licorice (甘草, Glycyrrhizae Radix et Rhizoma ) is a perennial plant belonging to the legume family, and is generally native or cultivated in northern China, Siberia, southern Italy, Manchuria, and Mongolia. Licorice is one of the medicinal herbs used as an ingredient that reduces toxicity in all herbal medicines and is used as an antitussive, and in Europe it is also used to sweeten cigarettes, gums, and candy.
금은화(金銀花, Lonicerae Flos)는 인동과의 인동덩굴(Lonicerajaponica Thunberg) 또는 그 변종의 꽃봉오리를 말한다. 금은화는 열을 내리고 가슴이 답답하고 갈증이 있을 때 사용하며 항균작용, 항염증작용, 해열작용을 하는 것으로 알려져 있다. Lonicerae Flos (金銀花, Lonicerae Flos ) refers to the honeysuckle (Lonicerajaponica Thunberg) or its varieties. Gold and silver coins are used when the fever is lowered, the chest is stuffy and thirsty, and is known to have antibacterial, anti-inflammatory, and antipyretic effects.
당귀(當歸, Angelicae Gigantis Radix)는 산형과(形科, Umbelliferae)에 속한 안젤리카(Angelica) 속 식물로서, 보혈작용이 현저하여 빈혈에 유효하고 일반 타박상이나 혈전성동맥염의 치료에도 응용되고 빈혈로 오는 두통과 관절염 등에 널리 사용한다 Angelicae Gigantis Radix is a plant belonging to the genus Angelica belonging to the Umbelliferae family. It is effective for anemia due to its remarkable blood-reserving action. It is also applied to the treatment of general bruises and thrombotic arteritis, and is also associated with anemia. Widely used for headaches and arthritis
방풍(防風, Saposhnikoviae Radix)은 미나리과(Umbelliferae)에 속하며, 진방풍, 산방풍, 병풍나물, 산방풍나무, 방풍나무뿌리 등으로 불리는 약용식물이다. 한방에서는 두해살이 뿌리를 감기와 두통, 발한과 거담에 약으로 쓴다. Bangpung (防風, Saposhnikoviae Radix ) belongs to the Umbelliferae, and is a medicinal plant called Jinbangpung , Sanbangpung , folding screen sprouts, Sanbangpung tree, and windbreak tree root. In oriental medicine, the root of two years old is used as medicine for colds, headaches, sweating and expectorant disease.
백작약(白芍藥, Paeonia japonica)은 모란과(Paeoniaceae)에 속하는 다년생 식물 작약(Paeonia japonica)의 뿌리로 한방에서 수렴, 완화, 진경, 진통약으로 사용한다. Paeonia japonica (白芍藥, Paeonia japonica ) is the root of the perennial plant peony (Paeonia japonica) belonging to the peony family (Paeoniaceae) and is used as astringent, alleviating, antispasmodic, and analgesic in oriental medicine.
백질려(白, Tribulus terrestris L.)는 남가새과(Zygophyllaceae)의 일년생 초본으로서 남가새, 납가새 라고도 한다. 한방에서는 남가새를 백질려, 자질려라고 부르며 열매를 질려자라고 호칭하고, 고혈압으로 어지럽고 두통이 심하며 우울할 때 복용하면 혈압을 내려주며, 눈이 충혈되고 눈물이 나며 시력이 감퇴되고 각막이 혼탁해지는 안과질환에 사용한다. Baekjiryo (白, Tribulus terrestris L.) is an annual herb of the Zygophyllaceae family. In oriental medicine, Namgasae is called Baekjillyeo, Jajillyeo, and the fruit is called ``get tired of the fruit'', and when taken when you are dizzy due to high blood pressure, severe headache, and depressed, it lowers blood pressure, redness of the eyes, tears, loss of vision, and corneal clouding. Used for
산사(山査; Crataegi Fructus)는 장미과(Rosaceae)에 속한 낙엽교목인 Crataegus pinnatifida의 열매를 건조한 것으로, 한의학에서는 비, 위, 간경에 작용하여 식적(食積)을 없애고 음식의 소화를 촉진시키며 어혈(瘀血)을 제거하는데 오래 전부터 널리 사용되고 있는 약재이다.Crataegi Fructus is a dried fruit of Crataegus pinnatifida, a deciduous tree belonging to the Rosaceae family.In oriental medicine, it acts on the rain, stomach, and liver to eliminate food and promote food digestion, It is a medicinal material that has been widely used for a long time to remove 瘀血).
생지황(生地黃, Rehmanniae Radix Crudus)은 현삼과(Scrophulariaceae) 식물인 지황(Rehmannia glutinosa Libosch.)의 근경으로, 주성분으로는 카탈폴(Catalpol), 베르바스코스 만니톨(Verbascose mannitol), 글루코스(Glucose), 마니노트리오스(Maninotriose), 비타민 A(Vitamin A)를 포함하고 있다. 생지황은 신음을 보하고 정(精)과 혈을 북돋아 주며, 혈증(血症)을 다스리는데 쓰인다. Rehmanniae Radix Crudus is a rhizome of Rehmannia glutinosa Libosch., a plant of the Scrophulariaceae family, and its main components are Catalpol, Verbascose mannitol, and Glucose. , Maninotriose, Vitamin A (Vitamin A). Saengjihwang is used to protect groaning, bolster jeong (精) and blood, and to control blood syndrome (血症).
승마(升麻, Cimicifugae Rhizoma)는 미나리아재비과에 속하는 여러해살이풀로 끼멸가리라고도 불리며, 승마와 그 동속 식물의 뿌리줄기는 약용으로 사용한다.Equestrian (升麻, Cimicifugae Rhizoma ) is a perennial plant belonging to the Ranunculus family, and is also called a stalk, and the rootstock of horseback riding and its genus is used for medicinal purposes.
우방자(牛蒡子, Arctii Semen)는 국화과에 속한 우엉의 성숙한 종자를 건조한 것이다. 우엉은 높이가 1.5m 정도로서 줄기는 위에서 가지가 갈라지고 뿌리는 굵고 길게 자라는 것으로 알려져 있다. 우방자는 소염 작용, 이뇨 작용, 완화 작용, 항균 작용 등을 한다.Woobangja (牛蒡子, Arctii Semen ) is the dried mature seeds of burdock belonging to the Asteraceae family. Burdock is known to have a height of 1.5m, and the stem is branched from above and the roots are known to grow thick and long. Allies have anti-inflammatory, diuretic, palliative, and antibacterial effects.
천궁(川芎, Cnidii Rhizoma)은 미나리과(Umbelliferae)에 속하는 다년생 초본으로 중국이 원산지로써 중국, 한국, 일본 등지에서 재배되고 있다. 한방에서는 천궁의 뿌리줄기를 풍냉으로 인한 두통, 동통, 빈혈, 월경불순, 불임 등과 같은 부인과질환의 치료에 이용하고 있다.Cnidium (川芎, Cnidii Rhizoma ) is a perennial herb belonging to the Umbelliferae family. It is native to China and is cultivated in China, Korea, and Japan. In oriental medicine, the rhizome of Chungoong is used to treat gynecological diseases such as headache, pain, anemia, menstrual impurities, and infertility caused by wind and cold.
현삼(玄蔘, Scrophulariae Radix)은 현삼과 다년생 초본으로 줄기는 모가지며 잎은 좁고 길게 생겼다. 해열제로 인후염, 종기, 림프선염에 사용한다.Hyeonsam(玄蔘, Scrophulariae Radix ) is a perennial herbaceous plant with Hyeonsam. The stems are angular and the leaves are narrow and long. As an antipyretic, it is used for sore throat, boils, and lymphadenitis.
형개(荊芥, Schizonepetae Spica)는 사초과(Cyperaceae)에 속하는 다년생 초본으로서 한국 남부 및 제주도에 자생하며, 그 성분으로는 피넨 (pinene), 캄펜(campene), 1,8-시네올(cineol), 리모넨(limonene), 등의 정유 성분을 함유한 것으로 진통작용, 항균작용이 알려져 있다.Hyeonggae (荊芥, Schizonepetae Spica ) is a perennial herb belonging to the Cyperaceae family, native to southern Korea and Jeju Island, and its components include pinene, campene, 1,8-cineol, and limonene. It contains essential oils such as (limonene), and is known for its analgesic and antibacterial properties.
화피(樺皮, Betulae Cortex)는 장미과의 낙엽 교목인 벚나무속(genus Prunus)으로부터 얻어진 줄기 껍질로서, 향기가 약간 있고 맛은 쓰고 열기를 식히거나 기침을 그치게 하고, 거담, 해독 및 살충 효능이 있다. Hwapi (樺皮, Betulae Cortex) is a stem bark obtained from genus Prunus, a deciduous tree of the Rosaceae family. It has a slight scent, tastes bitter , cools heat or stops coughing, and has expectorant, detoxifying and insecticidal effects. .
본 발명의 일 구체예에 따르면, 상기 추출물은 물, 탄소수 1 내지 4개의 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 부틸 아세테이트, 클로로포름, 디에틸에테르, 디클로로메탄, 헥산, 및 이들의 혼합물로 구성된 군으로부터 선택되는 용매로 추출된 것일 수 있다.According to an embodiment of the present invention, the extract is water, alcohol having 1 to 4 carbon atoms, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, butyl acetate, chloroform, diethyl ether, dichloromethane, hexane, and It may be extracted with a solvent selected from the group consisting of a mixture thereof.
본 발명의 일 구체예에 따르면, 상기 추출물은 100℃의 정제수(또는 증류수)를 용매로 하여 추출된 것일 수 있다.According to one embodiment of the present invention, the extract may be extracted using purified water (or distilled water) at 100°C as a solvent.
본 발명의 일 구체예에 따르면, 탄소수 1 내지 4개의 알코올은 메탄올 또는 에탄올일 수 있다. According to an embodiment of the present invention, the alcohol having 1 to 4 carbon atoms may be methanol or ethanol.
본 발명의 일 구체예에 따르면, "추출물"은 생약재의 추출 처리에 의하여 얻어지는 추출액, 추출액의 희석액이나 농축액, 추출액을 건조하여 얻어지는 건조물, 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. According to one embodiment of the present invention, the "extract" is an extract obtained by extraction treatment of herbal substances, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a preparation or purified product of the extract, or a mixture thereof, etc. It includes extracts of all formulations that can be formed using itself and extracts.
본 발명의 일 구체예에 따르면, 상기 추출물은 상술한 용매 추출법에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예를 들어, 일정한 분자량 컷-오프(cut-off) 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시한 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 추출물에 포함될 수 있다. 또한, 상기 혼합 생약 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. 예를 들면 혼합 생약 추출물은 살균 및 분무건조 과정을 거쳐서 분말 형태로 제조될 수 있으며, 70 내지 90의 온도에서 10 내지 40분 동안 살균한 후, 분무건조기를 이용하여 분말 형태로 제조될 수 있다. According to one embodiment of the present invention, the extract includes not only the extract by the solvent extraction method described above, but also an extract that has undergone a conventional purification process. For example, separation by using an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods may also be included in the extract of the present invention. In addition, the mixed herbal extract may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze drying or spray drying. For example, the mixed herbal extract can be prepared in a powder form through sterilization and spray drying processes, and 70 to 90 After sterilization at a temperature of 10 to 40 minutes, it can be prepared in powder form using a spray dryer.
본 발명의 일 구체예에 따르면, "혼합 생약 추출물" 또는 "혼합 추출물"은 상기 추출방법에 의해 각각 추출된 감초 추출물, 금은화 추출물, 당귀 추출물, 방풍 추출물, 백작약 추출물, 백질려 추출물, 산사 추출물, 생지황 추출물, 승마 추출물, 우방자 추출물, 천궁 추출물, 현삼 추출물, 형개 추출물 및 화피 추출물을 혼합한 것이나 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개 및 화피를 혼합한 혼합 생약재를 상기 추출방법에 의해 추출한 추출물을 의미할 수 있다.According to one embodiment of the present invention, "mixed herbal extracts" or "mixed extracts" are each extracted by the above extraction method licorice extract, gold and silver extract, angelica extract, windbreak extract, baekjak extract, baekjiri extract, hawthorn extract, Saengjihwang extract, horseback riding extract, wubangja extract, cheonggung extract, hyeonsam extract, hyeonggae extract and hwapi extract mixed or licorice, gold and silver flower, angelica, windbreak, baekjak, baekjiryo, hawthorn, saengjihwang, horseback riding, woobangja, cheonggung, hyeonsam, hyeonggae And it may mean an extract obtained by extracting the mixed herbal medicine mixed with Hwapi by the above extraction method.
본 발명의 일 구체예에 따르면, 혼합 추출물은 갈근 1 중량부에 감초 1 내지 2 중량부, 금은화 1 내지 2 중량부, 당귀 1 내지 2 중량부, 방풍 1 내지 2 중량부, 백작약 1 내지 2 중량부, 백질려 1 내지 2 중량부, 산사 1 내지 2 중량부, 생지황 1 내지 2 중량부, 승마 1 내지 2 중량부, 우방자 1 내지 2 중량부, 천궁 1 내지 2 중량부, 현삼 1 내지 2 중량부, 형개 1 내지 2 중량부 및 화피 1 내지 2 중량부를 혼합하여 추출한 것일 수 있다. According to one embodiment of the present invention, the mixed extract is 1 part by weight of prickly pear 1 part by weight of licorice 1 to 2 parts by weight, 1 to 2 parts by weight of gold and silver flowers, 1 to 2 parts by weight of Angelicae, 1 to 2 parts by weight of windbreak, 1 to 2 parts by weight of earl Part, 1 to 2 parts by weight of Baekjiryo, 1 to 2 parts by weight of Sansa, 1 to 2 parts by weight of Saengjihwang, 1 to 2 parts by weight of horseback riding, 1 to 2 parts by weight of woobangja, 1 to 2 parts by weight of Chungung, 1 to 2 parts by weight of Hyeonsam It may be extracted by mixing 1 to 2 parts by weight of parts, hyunggae and 1 to 2 parts by weight of hwapi.
본 발명의 일 구체예에 따르면, 혼합 추출물은 갈근 1 중량부에 감초 1 중량부, 금은화 2 중량부, 당귀 1 중량부, 방풍 1 중량부, 백작약 1 중량부, 백질려 1 중량부, 산사 1 중량부, 생지황 1 중량부, 승마 1 중량부, 우방자 1 중량부, 천궁 1 중량부, 현삼 1 중량부, 형개 1 중량부 및 화피 1 중량부를 혼합하여 추출한 것일 수 있다.According to an embodiment of the present invention, the mixed extract is 1 part by weight of Galgeun, 1 part by weight of licorice, 2 parts by weight of gold and silver flowers, 1 part by weight of Angelicae, 1 part by weight of windbreak, 1 part by weight of Earl, 1 part by weight of Baekjiri, 1 part by weight of hawthorn It may be extracted by mixing 1 part by weight of saengjihwang, 1 part by weight of horseback riding, 1 part by weight of ally, 1 part by weight of cheonggung, 1 part by weight of hyeonsam, 1 part by weight of hyunggae and 1 part by weight of hwapi.
본 발명의 일 구체예에 따르면, 혼합 추출물은 갈근 추출물 1 중량부에 감초 추출물 1 중량부, 금은화 추출물 2 중량부, 당귀 추출물 1 중량부, 방풍 추출물 1 중량부, 백작약 추출물 1 중량부, 백질려 추출물 1 중량부, 산사 추출물 1 중량부, 생지황 추출물 1 중량부, 승마 추출물 1 중량부, 우방자 추출물 1 중량부, 천궁 추출물 1 중량부, 현삼 추출물 1 중량부, 형개 추출물 1 중량부 및 화피 추출물 1 중량부를 혼합한 것일 수 있다. According to an embodiment of the present invention, the mixed extract is 1 part by weight of Galgeun extract, 1 part by weight of licorice extract, 2 parts by weight of gold and silver extract, Angelicae extract 1 part by weight, 1 part by weight of windbreak extract, 1 part by weight of Peony extract, Baekjiri 1 part by weight of extract, 1 part by weight of hawthorn extract, 1 part by weight of saengjihwang extract, 1 part by weight of horseback riding extract, 1 part by weight of wubangja extract, 1 part by weight of Chungoong extract, 1 part by weight of Hyeonsam extract, 1 part by weight of Hyeonggae extract and 1 part by weight of Hwapi extract It may be a mixture of parts by weight.
본 발명의 일 구체예에 따른 조성물은 조성물 총 중량에 대하여 혼합 생약 추출물을 0.001중량% 내지 99.99중량%, 바람직하게는 0.1중량% 내지 99중량%로 포함할 수 있으며, 이는 건선의 예방 또는 치료용 조성물의 사용방법 및 사용목적에 따라 본 발명이 속하는 기술분야의 통상의 지식을 가진 자에게 적절히 선택될 수 있다.The composition according to an embodiment of the present invention may contain from 0.001% to 99.99% by weight, preferably from 0.1% to 99% by weight of the mixed herbal extract based on the total weight of the composition, which is for the prevention or treatment of psoriasis Depending on the method of use and the purpose of use of the composition, it may be appropriately selected by those of ordinary skill in the art to which the present invention belongs.
본 발명의 일 구체예에 따르면, 혼합 생약 추출물은 1 내지 1000㎍/㎖, 10 내지 900㎍/㎖, 50 내지 700㎍/㎖ 또는 100 내지 500㎍/㎖의 농도로 조성물에 포함될 수 있다.According to one embodiment of the present invention, the mixed herbal extract may be included in the composition at a concentration of 1 to 1000 μg/ml, 10 to 900 μg/ml, 50 to 700 μg/ml, or 100 to 500 μg/ml.
본 발명의 일 구체예에 따른 혼합 생약 추출물을 포함하는 조성물은 IL-1α, IL-17A, IL-22, 온코스타틴 M(Oncostatin M) 및 TNF-α로 자극한 각질 형성 세포에서 CXCL8, CXCL10, 및 GM-CSF의 발현을 저해함으로써 우수한 건선 예방 또는 치료 효능을 제공할 수 있다. The composition comprising the mixed herbal extract according to an embodiment of the present invention is CXCL8, CXCL10, in keratinocytes stimulated with IL-1α, IL-17A, IL-22, Oncostatin M and TNF-α, And by inhibiting the expression of GM-CSF can provide excellent psoriasis prevention or treatment efficacy.
본 발명의 일 구체예에 따르면, 혼합 생약 추출물을 포함하는 조성물은 각질 형성 세포의 증식을 억제하는 것일 수 있다.According to one embodiment of the present invention, the composition containing the mixed herbal extract may be one to inhibit the proliferation of keratinocytes.
본 발명의 일 구체예에 따른 혼합 생약 추출물을 포함하는 조성물은 IL-22로 자극한 각질 형성 세포의 증식을 억제하여 우수한 건선 예방 또는 치료 효능을 제공할 수 있다.The composition comprising the mixed herbal extract according to an embodiment of the present invention can provide excellent psoriasis prevention or treatment efficacy by inhibiting the proliferation of keratinocytes stimulated with IL-22.
본 발명의 일 구체예에 따른 혼합 생약 추출물을 포함하는 조성물은 IL-22에 의해 발현이 증가된 증식 관련 인자인 KRT16의 발현을 저해하고, IL-22에 의해 발현이 감소된 분화 관련 인자인 인볼루크린(involucrin) 및 필라그린(filaggrin)의 발현을 촉진함으로써 우수한 건선 예방 또는 치료 효능을 제공할 수 있다. The composition comprising the mixed herbal extract according to an embodiment of the present invention inhibits the expression of KRT16, a proliferation-related factor with increased expression by IL-22, and phosphorus, a differentiation-related factor whose expression is reduced by IL-22. By promoting the expression of involucrin and filaggrin, it is possible to provide excellent psoriasis prevention or treatment efficacy.
본 발명의 일 구체예에 따른 혼합 생약 추출물을 포함하는 조성물은 건선성 피부에 사용되는 스테로이드제 덱사메타손(dexamethasone)에 비하여 우수한 효능을 보이고, 생약 추출물을 유효성분으로 포함하므로 스테로이드 제제보다 부작용이 적을 수 있다.The composition containing the mixed herbal extract according to an embodiment of the present invention exhibits superior efficacy compared to the steroid agent dexamethasone used for psoriatic skin, and contains the herbal extract as an active ingredient, so it may have fewer side effects than the steroid preparation. have.
본 발명의 일 구체예에 따른 약학적 조성물은 약제학적으로 허용 가능한 첨가제를 더 포함할 수 있으며, 이때 약제학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바 납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산 알루미늄, 스테아린산칼슘, 백당, 덱스트로스, 소르비톨 또는 탈크 등이 사용될 수 있다. The pharmaceutical composition according to an embodiment of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicone Dioxide, calcium hydrogen phosphate, lactose, mannitol, syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, sodium starch glycolate, lead carnauba, synthetic aluminum silicate, stearic acid, stearic acid Magnesium, aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol or talc may be used.
본 발명의 일 구체예에 따른 약학적 조성물은 약학적으로 허용되는 담체를 포함할 수 있다. 본 발명의 일 구체예에 따른 약학적 조성물에 포함되는 약학적으로 허용되는 담체는 약제의 제조시에 통상적으로 이용되는 것으로써, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 트레할로스, 히알루론산, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 또는 미네랄 오일 등이 사용될 수 있으나, 이에 한정되는 것은 아니다. 본 발명의 일 구체예에 따른 약학적 조성물은 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 또는 보존제 등을 추가로 포함할 수 있다. 약학적으로 허용되는 적합한 담체 및 제제는 Remington's Pharmaceutical Sciences (22th ed., 2013)에 상세히 기재되어 있다.The pharmaceutical composition according to an embodiment of the present invention may include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers included in the pharmaceutical composition according to an embodiment of the present invention are those commonly used in the manufacture of drugs, and are lactose, dextrose, sucrose, sorbitol, mannitol, trehalose, hyaluronic acid, Starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, Magnesium stearate or mineral oil may be used, but is not limited thereto. The pharmaceutical composition according to an embodiment of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, or a preservative. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (22th ed., 2013).
본 발명의 일 구체예에 따른 약학적 조성물은 실제 임상 투여 시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 본 발명의 지용성 폴리페놀 성분이 증가된 생약 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calciumcarbonate), 수크로스(Sucrose), 락토오스(Lactose) 또는 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용될 수 있다.The pharmaceutical composition according to an embodiment of the present invention can be administered in various oral and parenteral dosage forms at the time of actual clinical administration, but when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants It can be prepared using a diluent or excipient such as. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations are at least one excipient, such as starch, calcium in the herbal composition of the present invention with increased fat-soluble polyphenol components. It can be prepared by mixing carbonate, sucrose, lactose, or gelatin. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
본 발명의 일 구체예에 따른 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여할 수 있으며, 비경구 투여시 복강내주사, 직장내주사, 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택할 수 있다. 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도 등에 따라 그 범위가 다양하다.The pharmaceutical composition according to an embodiment of the present invention may be administered orally or parenterally according to a desired method, and when administered parenterally, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or chest You can choose my injection method. The dosage ranges vary depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and disease severity.
본 발명의 일 구체예에 따른 약학적 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에서 "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 일 구체예에 따른 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition according to an embodiment of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, drug activity, drug Sensitivity to, administration time, route of administration and rate of excretion, duration of treatment, factors including drugs used simultaneously, and other factors well known in the medical field. The composition according to an embodiment of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
구체적으로, 본 발명의 일 구체예에 따른 약학적 조성물의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 1kg 당 0.1㎎ 내지 200㎎, 바람직하게는 1㎎ 내지 10㎎을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나 투여 경로, 질환의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Specifically, the effective amount of the pharmaceutical composition according to an embodiment of the present invention may vary depending on the age, sex, and body weight of the patient, and is generally 0.1 mg to 200 mg, preferably 1 mg to 10 mg per 1 kg of body weight. May be administered daily or every other day, or divided into 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, the severity of the disease, sex, weight, age, etc., the dosage amount is not limited by any method.
본 발명의 일 구체예에 따른 약학적 조성물은 하나 이상의 건선에 활성을 나타내는 물질과 함께 투여될 수 있다.The pharmaceutical composition according to an embodiment of the present invention may be administered together with a substance exhibiting activity against one or more psoriasis.
본 발명의 일 구체예에 따른 약학적 조성물은 건선의 치료를 위하여 단독으로, 또는 예를 들면, 시술, 약물치료 및/또는 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition according to an embodiment of the present invention may be used alone for the treatment of psoriasis, or in combination with, for example, procedures, medications, and/or methods of using a biological response modifier.
본 발명의 다른 양상은 갈근, 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개 및 화피의 혼합 추출물을 유효성분으로 포함하는 건선 예방 또는 개선용 건강기능식품을 제공한다.Another aspect of the present invention is for the prevention or improvement of psoriasis comprising a mixed extract of Galgeun, Licorice, Geumeunhwa, Angelica, Bangpung, Baekjiryo, Sansa, Saengjihwang, Horseback Riding, Woobangja, Cheongung, Hyeonsam, Hyeonggae and Hwapi as an active ingredient Provide health functional food.
본 발명의 일 구체예에 따르면, 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 이의 염, 알긴산 및 이의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품은 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알콜 음료 및 비타민 복합제 중 어느 하나의 형태일 수 있다.According to one embodiment of the present invention, the health functional food includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid, and Salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. In addition, it may contain flesh for the manufacture of natural fruit juice and fruit juice beverages and vegetable beverages. These components may be used independently or in combination. In addition, health functional foods are in the form of any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcoholic beverage and vitamin complex. Can be
본 발명의 일 구체예에 따르면, 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합여부는 다른 규정이 없는 한 식품의약품안정청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.According to one embodiment of the present invention, the health functional food may additionally contain a food additive, and whether or not it is suitable as a "food additive" is a general rule and general test of the Food Additive Code approved by the Food and Drug Administration unless otherwise specified. Judgment is made according to the standards and standards for the relevant item in accordance with the law.
본 발명의 일 구체예에 따르면, "식품첨가물공전"에 기재된 품목으로서 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀롤로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류들을 들 수 있다.According to one embodiment of the present invention, chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, cinnamic acid, etc. as items described in the "Food Additives Code", reduced pigment, licorice extract, crystalline cellulose, high cooling pigment, guar gum, etc. Mixed preparations such as natural additives, sodium L-glutamate, alkali additives for noodles, preservatives, and tar colorants.
본 발명의 또 다른 양상은 갈근, 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개 및 화피의 혼합 추출물을 유효성분으로 포함하는 건선 예방 또는 개선용 화장료 조성물을 제공한다.Another aspect of the present invention is the prevention or improvement of psoriasis comprising a mixed extract of Galgeun, Licorice, Geumeunhwa, Angelica, Bangpung, Baekjiryo, Sansa, Saengjihwang, Horseback Riding, Woobangja, Cheongung, Hyeonsam, Hyeonggae and Hwapi as active ingredients It provides a cosmetic composition for.
본 발명의 일 구체예에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition according to an embodiment of the present invention is a solution, external ointment, cream, foam, nutritional lotion, softening lotion, pack, softening water, emulsion, makeup base, essence, soap, liquid cleaning agent, bathing agent, sunscreen cream, sun Oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray can be prepared in a formulation selected from the group consisting of , But is not limited thereto.
본 발명의 일 구체예에 따르면, 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 한정되는 것은 아니다.According to one embodiment of the present invention, the cosmetic composition may additionally include one or more cosmetically acceptable carriers that are blended in general skin cosmetics. , Lower alcohols, thickeners, chelating agents, pigments, preservatives, flavors, etc. may be appropriately blended, but are not limited thereto.
본 발명의 일 구체예에 따르면, 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.According to one embodiment of the present invention, the cosmetically acceptable carrier included in the cosmetic composition varies depending on the formulation.
본 발명의 일 구체예에 따른 화장료 조성물의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the cosmetic composition according to an embodiment of the present invention is an ointment, paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite as a carrier component , Silica, talc, zinc oxide or mixtures thereof may be used.
본 발명의 일 구체예에 따른 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the cosmetic composition according to an embodiment of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component. In particular, in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether may be additionally included.
본 발명의 일 구체예에 따른 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the cosmetic composition according to an embodiment of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol , Benzyl benzoate, propylene glycol, 1,3-butyl glycol oil may be used, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or sour Non-fat fatty acid esters can be used.
본 발명의 일 구체예에 따른 화장료 조성물의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition according to an embodiment of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbate Suspension agents such as non-esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth, and the like can be used.
본 발명의 일 구체예에 따른 혼합 생약 추출물을 포함하는 조성물은 생약 추출물을 유효성분으로 포함하고 있어 부작용이 없이 안전하게 사용이 가능하고 각질 형성 세포 증식을 억제하여 건선을 효과적으로 예방, 개선 또는 치료할 수 있다.The composition comprising the mixed herbal extract according to an embodiment of the present invention contains the herbal extract as an active ingredient, so it can be safely used without side effects, and can effectively prevent, improve or treat psoriasis by inhibiting the proliferation of keratinocytes. .
도 1a 내지 도 1c 는 IL-1α, IL-17A, IL-22, Oncostatin M 및 TNF-α의 조합(M5)으로 유도된 케모카인의 발현 증가에 대한 혼합 생약 추출물의 효과를 나타낸다. 구체적으로, 도 1a는 CXCL8, 도 1b는 CXCL10, 및 도 1c는 GM-CSF의 발현양을 나타낸다.
도 2는 IL-22로 유도된 각질 형성 세포의 증식에 대한 혼합 생약 추출물의 세포 증식 억제 효과를 나타낸다.
도 3a 내지 3c는 3D 인간 피부 재구성 모델에서 IL-22로 유도된 KRT 16의 발현 증가와 인볼루크린 및 필라그린의 발현 감소에 대한 혼합 생약 추출물의 효과를 나타낸다. 구체적으로 도 3a 는 KRT 16, 도 3b는 인볼루크린, 및 도 3c는 필라그린의 발현양을 나타낸다.1A to 1C show the effect of mixed herbal extracts on increasing the expression of chemokines induced by the combination of IL-1α, IL-17A, IL-22, Oncostatin M and TNF-α (M5). Specifically, FIG. 1A shows CXCL8, FIG. 1B shows CXCL10, and FIG. 1C shows the expression levels of GM-CSF.
2 shows the cell proliferation inhibitory effect of the mixed herbal extract on the proliferation of keratinocytes induced by IL-22.
3A to 3C show the effects of mixed herbal extracts on increasing the expression of KRT 16 induced by IL-22 and decreasing the expression of involukrin and filaggrin in a 3D human skin reconstruction model. Specifically, FIG. 3a shows the expression level of KRT 16, FIG. 3B shows involucrin, and FIG. 3C shows the expression level of filagreen.
이하, 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예 1. 혼합 생약 추출물의 제조.Example 1. Preparation of mixed herbal extracts.
갈근, 감초, 금은화, 당귀, 방풍, 백작약, 백질려, 산사, 생지황, 승마, 우방자, 천궁, 현삼, 형개, 및 화피(강동경희대학교 한방병원, 대한민국)를 물로 세척하여 이물질을 제거하였다. 갈근 4g, 감초 4g, 금은화 8g, 당귀 4g, 방풍 4g, 백작약 4g, 백질려 4g, 산사 4g, 생지황 4g, 승마 4g, 우방자 4g, 천궁 4g, 현삼 4g, 형개 4g, 및 화피 4g의 혼합물을 증류수로 100℃에서 3시간 동안 추출하였다. 추출물을 와트만 필터 페이퍼를 통과시켜 여과하고, 회전식 진공 증발기에서 증발시킨 후, 동결건조 하여 수득된 건조 분말을 증류수에 용해시키고, 0.22㎛ 주사기 필터를 통과시켜 멸균한 혼합 생약 추출물을 사용하였다. 이하, 혼합 생약 추출물을 D1으로 명명하였다.Galgeun, licorice, gold and silver flower, angelica, windbreak, earl medicine, baekjiryo, sansa, saengjihwang, horseback riding, ally, cheonggung, hyeonsam, hyeonggae, and hwapi (Gangdong Kyunghee University Oriental Medicine Hospital, Korea) were washed with water to remove foreign substances. Distilled water a mixture of 4g Galgeun, 4g Licorice, 8g Gold and Silver, Angelica 4g, 4g Windbreak, 4g Earl, 4g Baekjirye, 4g Sansa, 4g Saengjihwang, 4g Horse Riding, 4g Friendship 4g, 4g Cheongung, 4g Hyeonsam, 4g Hyeonggae, and 4g Hwapi Extracted at 100° C. for 3 hours. The extract was filtered through Whatman filter paper, evaporated in a rotary vacuum evaporator, and then freeze-dried to dissolve the obtained dry powder in distilled water, and then pass through a 0.22 μm syringe filter to use a sterilized mixed herbal extract. Hereinafter, the mixed herbal extract was named D1.
실시예 2. 항 건선 효과Example 2. Anti-psoriatic effect
<2-1> 세포배양<2-1> Cell culture
인간 각질 형성 세포주인 HaCaT 세포(Thermo Fisher Scientific, Waltham, MA, USA)를 10% 열 불활성화 소태아혈청, 100units/㎖ 페니실린 및 100㎍/㎖ 스트렙토마이신(Invitrogen, Carlsbad, CA)이 보충된 고함량 DMEM(Dulbecco's modified Eagle's medium; Gibco Laboratories, Grand Island, NY)에서 37℃ 5% CO2 습윤한 환경에서 배양하였다. 서브컨플루언스(sub-confluence) 도달 후, 세포를 실시예 1에서 제조한 혼합 생약 추출물의 처리 전에 무 혈청 배지에서 24 시간 동안 혈청 기아(serum-starved) 상태에 두었다.HaCaT cells (Thermo Fisher Scientific, Waltham, MA, USA), a human keratinocyte line, were supplemented with 10% heat inactivated fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA). Content DMEM (Dulbecco's modified Eagle's medium; Gibco Laboratories, Grand Island, NY) was cultured in a humid environment at 37° C. 5% CO 2 . After reaching sub-confluence, cells were placed in a serum-starved state for 24 hours in a serum-free medium before treatment with the mixed herbal extract prepared in Example 1.
<2-2> CXCL8, CXCL10, 및 GM-CSF의 저해 활성 측정<2-2> Measurement of inhibitory activity of CXCL8, CXCL10, and GM-CSF
각질 형성 세포인 HaCaT 세포를 상기 실시예 1에서 제조한 D1(100, 500㎍/㎖) 또는 덱사메타손(DEX, dexamethasone 10μM) 10% heat-inactivated fetal bovine serum, 100U/㎖의 페니실린, 100㎍/㎖ 스트렙토마이신이 함유된 DMEM 배지로 37℃의 온도, 5% CO2 환경에서 배양한 다음 IL-1α, IL-17A, IL-22, 온코스타틴 M(oncostatin M) 및 TNF-α의 조합(이하, M5)으로 HaCaT 세포를 자극하였다. 시판용 키트(Koma Biotech, Seoul, Korea 또는 R & D Systems, Minneapolis, MN, USA)를 사용하여 배양 상등액 중의 인간 CXCL8(C-X-C motif ligand 8), CXCL10(C-X-C motif ligand 10), 또는 GM-CSF(granulocyte-macrophage colony-stimulating factor)의 농도를 효소면역분석(ELISA)을 수행하여 측정하였다. 흡광도는 자동화된 마이크로 플레이트 판독기(Molecular Devices, Sunnyvale, CA)를 사용하여 450 내지 550 nm에서 측정하였다. D1 (100, 500 μg/ml) or dexamethasone (DEX,
도 1a 내지 도 1c는 IL-1α, IL-17A, IL-22, Oncostatin M 및 TNF-α(M5)의 조합으로 유도된 케모카인 발현 증가에 대한 혼합 생약 추출물의 효과를 나타낸다. 구체적으로, 도 1a는 CXCL8, 도 1b는 CXCL10, 및 도 1c는 GM-CSF의 발현양을 나타낸다. 도 1a 내지 도 1c에서 normal은 M5, D1 및 덱사메타손이 처리되지 않은 대조군을 의미한다.1A to 1C show the effect of mixed herbal extracts on increasing chemokine expression induced by the combination of IL-1α, IL-17A, IL-22, Oncostatin M, and TNF-α (M5). Specifically, FIG. 1A shows CXCL8, FIG. 1B shows CXCL10, and FIG. 1C shows the expression levels of GM-CSF. In FIGS. 1A to 1C, normal means a control group to which M5, D1, and dexamethasone are not treated.
도면에 나타난 바와 같이, M5를 각질 형성 세포에 처리하면, CXCL8, CXCL10, 또는 GM-CSF의 발현양이 증가하고, D1을 첨가시에 증가하였던 CXCL8, CXCL10, 또는 GM-CSF의 발현양이 농도 의존적으로 감소하는 것을 알 수 있다. 또한 500㎍/㎖의 D1을 처리한 실험군에서는 덱사메타손 대비 CXCL8, CXCL10, GM-CSF 저해 활성이 훨씬 우수한 것을 알 수 있었다.As shown in the figure, when M5 is treated with keratinocytes, the expression level of CXCL8, CXCL10, or GM-CSF increases, and the concentration of the expression level of CXCL8, CXCL10, or GM-CSF increased when D1 is added. It can be seen that it decreases dependently. In addition, it was found that in the experimental group treated with D1 at 500 μg/ml, the inhibitory activity of CXCL8, CXCL10, and GM-CSF was much better than that of dexamethasone.
<2-3> 각질 형성 세포 증식 분석<2-3> Keratinocyte proliferation assay
HaCaT 세포의 증식은 증식 중인 세포 안의 새롭게 합성된 DNA를 BrdU(5-bromo-2'-deoxy-uridine) 항체로 검출하는 BrdU 세포 증식 ELISA 분석 키트(Cell Biolabs, San Diego, CA)를 이용하여 측정하였다. HaCaT 세포를 실시예 1에서 제조한 D1(100, 500㎍/㎖) 또는 DEX(10μM)로 1시간 동안 전처리 한 다음 24 시간 동안 IL-22(100ng/㎖)를 처리하였다. 이 세포들을 BrdU-표지 용액 10㎕로 4시간 동안 인큐베이션하였다. 마이크로 플레이트 판독기를 사용하여 450nm에서 흡광도를 측정하였다.The proliferation of HaCaT cells was measured using a BrdU cell proliferation ELISA assay kit (Cell Biolabs, San Diego, CA) that detects newly synthesized DNA in proliferating cells with a BrdU (5-bromo-2'-deoxy-uridine) antibody. I did. HaCaT cells were pretreated with D1 (100, 500 μg/ml) or DEX (10 μM) prepared in Example 1 for 1 hour and then treated with IL-22 (100 ng/ml) for 24 hours. These cells were incubated with 10 μl of BrdU-labeled solution for 4 hours. Absorbance was measured at 450 nm using a micro plate reader.
도 2는 IL-22로 유도된 각질 형성 세포의 증식에 대한 혼합 생약 추출물의 세포 증식 억제 효과를 나타낸다. 도 2에서 normal은 IL-22, D1 및 덱사메타손이 처리되지 않은 대조군을 의미한다.2 shows the cell proliferation inhibitory effect of the mixed herbal extract on the proliferation of keratinocytes induced by IL-22. In FIG. 2, normal means a control group to which IL-22, D1 and dexamethasone are not treated.
IL-22는 각질 형성 세포 내 항미생물제(antimicrobial agents)와 β-defensins를 유도시키고 상피의 과형성을 촉진하므로, 예상대로 HaCaT 세포에 IL-22를 처리시 세포의 증식이 유도되었다. 도면에 나타난 바와 같이 IL-22 처리군에서 BrdU 양성 세포수가 증가하였고, D1 첨가시 각질 형성 세포의 증식이 농도 의존적으로 억제된 것을 알 수 있다.IL-22 induces antimicrobial agents and β-defensins in keratinocytes and promotes epithelial hyperplasia. As expected, treatment with IL-22 on HaCaT cells induced cell proliferation. As shown in the figure, the number of BrdU-positive cells in the IL-22 treatment group increased, and when D1 was added, the proliferation of keratinocytes was inhibited in a concentration-dependent manner.
<2-4> KRT 16(Keratin 16)의 발현 저해 및 인볼루크린(involucrin), 필라그린(filaggrin)의 발현 증가 측정<2-4> Inhibition of KRT 16 (Keratin 16) expression and measurement of increased expression of involucrin and filaggrin
NeodermED®(Tegoscience, Seoul, Korea)는 각질 형성 세포 (keratinocytes)와 피부 섬유아세포가 인간의 피부의 형태와 생리를 모방하도록 3차원적으로 배양되어 상업적으로 이용 가능한 인간 피부 재구성 모델이다. 3D 인간 피부 재구성 모델(3D human skin reconstructed model)을 제조사가 제공한 1㎖의 배지를 포함하는 12-웰 플레이트에 배치하였다. 다음으로, 3일 동안 20ng/㎖의 IL-22로 3D 피부 재생 모델을 자극하였다. 치료를 위해 IL-22로 자극된 3D 피부 재구성 모델을 실시예 1에서 제조한 D1(100, 500㎍/㎖)으로 처리하였다. 3D 인간 피부 재구성 모델을 차가운 조직 추출 시약(Thermo Fisher Scientific, Rockford, IL)으로 균질화시키고, 12,000g에서 20분 동안 원심 분리시켰다. 용해물 중의 KRT16, 인볼루크린 및 필라그린의 발현양을 시판되는 ELISA 키트(Koma Biotech, Seoul, Korea)를 사용하여 측정하였다. 흡광도는 자동화된 마이크로 플레이트 판독기를 사용하여 450 내지 550nm에서 측정하였다.NeodermED ® (Tegoscience, Seoul, Korea) is a commercially available human skin reconstruction model in which keratinocytes and skin fibroblasts are cultured in three dimensions to mimic the morphology and physiology of human skin. A 3D human skin reconstructed model was placed in a 12-well plate containing 1 ml of medium provided by the manufacturer. Next, the 3D skin regeneration model was stimulated with 20 ng/ml of IL-22 for 3 days. For treatment, a 3D skin reconstruction model stimulated with IL-22 was treated with D1 (100, 500 μg/ml) prepared in Example 1. The 3D human skin reconstruction model was homogenized with cold tissue extraction reagent (Thermo Fisher Scientific, Rockford, IL) and centrifuged at 12,000 g for 20 minutes. The expression levels of KRT16, involukrin, and filaggrin in the lysate were measured using a commercially available ELISA kit (Koma Biotech, Seoul, Korea). Absorbance was measured at 450-550 nm using an automated micro plate reader.
도 3a 내지 3c는 3D 인간 피부 재구성 모델에서 IL-22로 유도된 KRT 16의 발현 증가 및 인볼루크린(Involucrin), 필라그린(Filaggrin)의 발현 감소에 대한 혼합 생약 추출물의 효과를 나타낸다. 구체적으로 도 3a는 KRT 16, 도 3b는 인볼루크린, 및 도 3c는 필라그린의 발현양을 나타낸다. 도 3a 내지 3c에서 NC는 IL-22 및 D1이 처리되지 않은 대조군을 의미한다.3A to 3C show the effects of mixed herbal extracts on increasing the expression of KRT 16 induced by IL-22 and decreasing the expression of Involucrin and Filaggrin in a 3D human skin reconstruction model. Specifically, FIG. 3A shows the expression levels of KRT 16, FIG. 3B shows involucrin, and FIG. 3C shows the expression level of filagreen. In Figures 3a to 3c, NC refers to a control group that is not treated with IL-22 and D1.
IL-22는 인볼루크린 및 필라그린과 같은 각질 형성 세포의 분화와 관련된 유전자의 발현을 억제하고, KRT 16의 발현은 증가시킨다고 알려져 있으므로 예상대로 세포에 IL-22 처리시 KRT 16의 발현양은 증가하고 인볼루크린 및 필라그린의 발현양은 감소하였다. 도 3a 내지 도 3c에 나타난 바와 같이 D1 첨가시, IL-22로 증가된 KRT16의 발현은 저해되고 IL-22 처리로 발현이 저해된 인볼루크린 및 필라그린의 발현은 농도 의존적으로 증가되는 것을 알 수 있다.IL-22 inhibits the expression of genes related to the differentiation of keratinocytes such as involucrin and filaggrin, and is known to increase the expression of KRT 16. As expected, when IL-22 is treated in cells, the amount of expression of KRT 16 increases. And the expression levels of involucrin and filaggrin were decreased. As shown in FIGS. 3A to 3C, when D1 was added, the expression of KRT16 increased by IL-22 was inhibited, and the expression of involucrine and filagrin, which was inhibited by IL-22 treatment, was increased in a concentration-dependent manner. I can.
Claims (6)
A cosmetic composition for preventing or improving psoriasis, comprising a mixed extract of Galgeun, Licorice, Geumeunhwa, Angelica, Bangpung, Earl, Baekjiryo, Sansa, Saengjihwang, Horseback Riding, Woobangja, Cheongung, Hyeonsam, Hyeonggae and Hwapi as active ingredients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190102010A KR102197858B1 (en) | 2019-08-20 | 2019-08-20 | Composition for preventing or treating psoriasis comprising herb mixtures |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190102010A KR102197858B1 (en) | 2019-08-20 | 2019-08-20 | Composition for preventing or treating psoriasis comprising herb mixtures |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102197858B1 true KR102197858B1 (en) | 2021-01-05 |
Family
ID=74140807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190102010A KR102197858B1 (en) | 2019-08-20 | 2019-08-20 | Composition for preventing or treating psoriasis comprising herb mixtures |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102197858B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230062702A (en) | 2021-10-29 | 2023-05-09 | 부경대학교 산학협력단 | Composition for psoriasis treatment with nanoemulsion containing plastoquinone concentrate isolated from Sargassum serratifolium |
KR20240012199A (en) | 2022-07-20 | 2024-01-29 | (주)비엔 | Composition for improving psoriasis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150084019A (en) | 2012-10-23 | 2015-07-21 | 피라말 엔터프라이지즈 리미티드 | HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASE |
-
2019
- 2019-08-20 KR KR1020190102010A patent/KR102197858B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150084019A (en) | 2012-10-23 | 2015-07-21 | 피라말 엔터프라이지즈 리미티드 | HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASE |
Non-Patent Citations (1)
Title |
---|
우수경험방집. 편명: 피부 및 피하질환(皮膚 및 皮下疾患)-피부(皮膚) (2004년) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230062702A (en) | 2021-10-29 | 2023-05-09 | 부경대학교 산학협력단 | Composition for psoriasis treatment with nanoemulsion containing plastoquinone concentrate isolated from Sargassum serratifolium |
KR20240012199A (en) | 2022-07-20 | 2024-01-29 | (주)비엔 | Composition for improving psoriasis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100540033B1 (en) | Crude Drug Compositions for treating or preventing arthritic diseases and the process for preparing them | |
KR20110051162A (en) | Composition for immune enhancement comprising the extract of young antler, cornus officinalis, ligusticum acutilobum, aurantii nobilis pericarpium, chinese matrimony vine, lotus root, yam, curcuma aromatica salisb, gastrodia elata blume, agastache rugosa, cinnamomum loureirii, ginseng steamed red and schizandra chinensis, as active ingredient | |
KR101751398B1 (en) | Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation | |
CN102573787A (en) | Composition containing a natural extract | |
KR20200106577A (en) | Composition for anti-oxidant, anti-inflammatory and relieving swelling containing plant complex extracts | |
WO2019132625A1 (en) | Composition for preventing, improving or treating atopic dermatitis containing mixed herbal extract as active ingredient | |
Nirmala et al. | Promising underutilized wild plants of cold desert Ladakh, India for nutritional security and health benefits | |
KR102197858B1 (en) | Composition for preventing or treating psoriasis comprising herb mixtures | |
KR20130077314A (en) | Pharmaceutical composition and cosmetic compostion for improving skin condition and preparation method thereof | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
KR102081066B1 (en) | Composition for enhancing skin barrier comprising ultra high-pressure oriental herb extract as effective component | |
KR101891218B1 (en) | Composition for treatment of dermatitis comprising natural plant extracts | |
WO2016117705A1 (en) | Agent for inducing production of hepatocyte growth factor | |
KR101566822B1 (en) | Cosmetic containing herb extracts for improving atopic dermatitis | |
KR101213054B1 (en) | Composition for the prevention and treatment of apotic dermatitis containing the mixed extract of Chrysanthemum indicum Linne. and steamed Rheum undulatum with alcohol as an effective ingredient | |
KR101093730B1 (en) | Smilax china extracts compositions for treating or preventing inflammatory diseases | |
KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
KR101088299B1 (en) | Pharmaceutical composition containing a herbal extract for preventing and treating nephritis | |
KR20190092714A (en) | Composition for improving cognitive funtion and method for producing the same | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
KR101769123B1 (en) | Cosmetic composition containing natural complex extract for improving atopic dermatitis | |
KR20200071380A (en) | Composition for improving premenstrual syndrome symptom comprising extract of Aucklandiae radix | |
KR20150002048A (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
CN109568496B (en) | Detection method of traditional Chinese medicine composition for treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |